DK2776567T3 - Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. - Google Patents

Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. Download PDF

Info

Publication number: DK2776567T3
Authority: DK; Denmark
Prior art keywords: cytomegalovirus; compositions; treatment; methods
Prior art date: 2011-11-11

Application number

DK12847559.7T

Other languages

English (en)

Inventor

David E Anderson

Anne-Catherine Fluckiger

Original Assignee

Variation Biotechnologies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-11

Filing date

2012-11-09

Publication date

2021-04-26

2012-11-09 Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc

2021-04-26 Application granted granted Critical

2021-04-26 Publication of DK2776567T3 publication Critical patent/DK2776567T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20245—Special targeting system for viral vectors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Lubricants (AREA)
Medicinal Preparation (AREA)

DK12847559.7T 2011-11-11 2012-11-09 Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. DK2776567T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161558800P	2011-11-11	2011-11-11
US201261654157P	2012-06-01	2012-06-01
PCT/IB2012/002854 WO2013068847A2 (en)	2011-11-11	2012-11-09	Compositions and methods for treatment of cytomegalovirus

Publications (1)

Publication Number	Publication Date
DK2776567T3 true DK2776567T3 (da)	2021-04-26

Family

ID=48290708

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK12847559.7T DK2776567T3 (da)	2011-11-11	2012-11-09	Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.

Country Status (14)

Country	Link
US (3)	US9777043B2 (da)
EP (2)	EP3854416A1 (da)
JP (2)	JP6232544B2 (da)
KR (2)	KR102301463B1 (da)
CN (3)	CN111995664B (da)
AU (3)	AU2012335277B2 (da)
BR (2)	BR112014011229B1 (da)
CA (2)	CA2889659C (da)
DK (1)	DK2776567T3 (da)
ES (1)	ES2874233T3 (da)
MX (2)	MX353189B (da)
PT (1)	PT2776567T (da)
RU (2)	RU2019139064A (da)
WO (1)	WO2013068847A2 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010148275A2 (en)	2009-06-18	2010-12-23	Kiyatec, Llc	Bioreactor system
CA2807552A1 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
EP3431485B2 (en)	2010-10-01	2024-09-04	ModernaTX, Inc.	Engineered nucleic acids and methods of use thereof
WO2012135805A2 (en)	2011-03-31	2012-10-04	modeRNA Therapeutics	Delivery and formulation of engineered nucleic acids
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
EP2763701B1 (en)	2011-10-03	2018-12-19	Moderna Therapeutics, Inc.	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA2889659C (en)	2011-11-11	2023-03-14	Variation Biotechnologies Inc.	Compositions and methods for treatment of cytomegalovirus
KR20140102759A (ko)	2011-12-16	2014-08-22	모더나 세라퓨틱스, 인코포레이티드	변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
EP2831285B1 (en) *	2012-03-27	2019-10-30	Variation Biotechnologies Inc.	Methods for detection of anti-cytomegalovirus neutralizing antibodies
US9878056B2 (en)	2012-04-02	2018-01-30	Modernatx, Inc.	Modified polynucleotides for the production of cosmetic proteins and peptides
DE18200782T1 (de)	2012-04-02	2021-10-21	Modernatx, Inc.	Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US20150359879A1 (en) *	2012-10-30	2015-12-17	Redvax Gmbh	Recombinant particle based vaccines against human cytomegalovirus infection
CA2892529C (en)	2012-11-26	2023-04-25	Moderna Therapeutics, Inc.	Terminally modified rna
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US9340799B2 (en)	2013-09-06	2016-05-17	President And Fellows Of Harvard College	MRNA-sensing switchable gRNAs
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru)	2013-10-03	2016-08-31	Модерна Терапьютикс, Инк.	Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
EP3158058B1 (en)	2014-06-18	2019-04-17	MorphoSys AG	Fusion proteins and uses thereof
KR101678740B1 (ko) *	2014-10-24	2016-11-23	단국대학교 천안캠퍼스 산학협력단	세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질
WO2016149426A1 (en) *	2015-03-16	2016-09-22	The Broad Institute, Inc.	Constructs for continuous monitoring of live cells
JP7059179B2 (ja)	2015-10-20	2022-04-25	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	遺伝子操作のための方法及び製品
MA46316A (fr)	2015-10-22	2021-03-24	Modernatx Inc	Vaccin contre le cytomégalovirus humain
US10611800B2 (en)	2016-03-11	2020-04-07	Pfizer Inc.	Human cytomegalovirus gB polypeptide
WO2017162265A1 (en)	2016-03-21	2017-09-28	Biontech Rna Pharmaceuticals Gmbh	Trans-replicating rna
WO2018075980A1 (en)	2016-10-21	2018-04-26	Modernatx, Inc.	Human cytomegalovirus vaccine
EP3592381A1 (en)	2017-03-09	2020-01-15	President and Fellows of Harvard College	Cancer vaccine
CN111801345A (zh)	2017-07-28	2020-10-20	哈佛大学的校长及成员们	使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
WO2019209632A1 (en) *	2018-04-24	2019-10-31	Merck Sharp & Dohme Corp.	Scalable chromatography process for purification of human cytomegalovirus
CN112638411B (zh)	2018-05-04	2025-03-04	斯拜生物技术有限公司	疫苗组合物
US11629172B2 (en)	2018-12-21	2023-04-18	Pfizer Inc.	Human cytomegalovirus gB polypeptide
US12351837B2 (en)	2019-01-23	2025-07-08	The Broad Institute, Inc.	Supernegatively charged proteins and uses thereof
US12473543B2 (en)	2019-04-17	2025-11-18	The Broad Institute, Inc.	Adenine base editors with reduced off-target effects
CA3142110A1 (en) *	2019-05-31	2020-12-03	Variation Biotechnologies Inc.	Immunotherapeutic compositions for treatment of glioblastoma multiforme
CN114258398A (zh)	2019-06-13	2022-03-29	总医院公司	工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
GB201910651D0 (en) *	2019-07-25	2019-09-11	Autolus Ltd	Virus-like particle
CN114466659A (zh) *	2019-09-09	2022-05-10	葛兰素史克生物有限公司	免疫治疗组合物
TWI810589B (zh)	2020-06-21	2023-08-01	美商輝瑞股份有限公司	人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
BR112023001272A2 (pt)	2020-07-24	2023-04-04	Massachusetts Gen Hospital	Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
US11406703B2 (en)	2020-08-25	2022-08-09	Modernatx, Inc.	Human cytomegalovirus vaccine
CN115948468A (zh) *	2022-09-09	2023-04-11	青岛大学	一种人巨细胞病毒重组载体及其制备方法和应用
WO2024243675A1 (en) *	2023-06-02	2024-12-05	Variation Biotechnologies Inc.	Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6267965B1 (en)	1981-12-24	2001-07-31	Virogenetics Corporation	Recombinant poxvirus—cytomegalovirus compositions and uses
JPS61103895A (ja) *	1984-10-26	1986-05-22	Green Cross Corp:The	ＨＢｓＡｇの精製方法
EP0436537A4 (en) *	1988-01-29	1992-04-08	Chiron Corporation	Recombinant cmv neutralizing proteins
US5500161A (en)	1993-09-21	1996-03-19	Massachusetts Institute Of Technology And Virus Research Institute	Method for making hydrophobic polymeric microparticles
DE19856463B4 (de) *	1998-11-26	2006-02-02	Heinrich-Pette-Institut	Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
DE19910044A1 (de)	1999-03-08	2000-09-14	Bodo Plachter	Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
JP2003512305A (ja) *	1999-09-30	2003-04-02	ユニバーシティオブワシントン	免疫学的に重要な単純疱疹ウイルス抗原
EP1201750A1 (en) *	2000-10-26	2002-05-02	Genopoietic	Synthetic viruses and uses thereof
US9045727B2 (en) *	2002-05-17	2015-06-02	Emory University	Virus-like particles, methods of preparation, and immunogenic compositions
DK2311848T3 (da)	2002-12-23	2013-10-14	Vical Inc	Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion
EP1651666B1 (en)	2003-07-11	2009-05-27	Alphavax, Inc.	Alphavirus-based cytomegalovirus vaccines
RU2290204C1 (ru) *	2005-07-27	2006-12-27	Общество с ограниченной ответственностью "Аванген"	Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
WO2008094200A2 (en) *	2006-07-27	2008-08-07	Ligocyte Pharmaceuticals, Inc	Chimeric virus-like particles
US20090123494A1 (en)	2007-07-31	2009-05-14	William Staplin	Momlv-based pseudovirion packaging cell line
US20110250675A1 (en)	2008-03-26	2011-10-13	Life Technologies Corporaiton	Virus-Like Particle Mediated Cellular Delivery
GB0907935D0 (en)	2009-05-08	2009-06-24	Henderson Morley Plc	Vaccines
CA2889659C (en)	2011-11-11	2023-03-14	Variation Biotechnologies Inc.	Compositions and methods for treatment of cytomegalovirus
CN106102769A (zh) *	2013-12-11	2016-11-09	促进军事医学的亨利·M·杰克逊基金会公司	人疱疹病毒三聚糖蛋白B、包含三聚gB的蛋白复合体及其作为疫苗的用途

2012
- 2012-11-09 CA CA2889659A patent/CA2889659C/en active Active
- 2012-11-09 AU AU2012335277A patent/AU2012335277B2/en active Active
- 2012-11-09 CN CN202010272504.4A patent/CN111995664B/zh active Active
- 2012-11-09 RU RU2019139064A patent/RU2019139064A/ru unknown
- 2012-11-09 EP EP21152309.7A patent/EP3854416A1/en active Pending
- 2012-11-09 PT PT128475597T patent/PT2776567T/pt unknown
- 2012-11-09 JP JP2014540570A patent/JP6232544B2/ja active Active
- 2012-11-09 RU RU2014123465A patent/RU2737530C1/ru active
- 2012-11-09 CN CN201711042348.7A patent/CN107875382B/zh active Active
- 2012-11-09 WO PCT/IB2012/002854 patent/WO2013068847A2/en not_active Ceased
- 2012-11-09 US US14/357,423 patent/US9777043B2/en active Active
- 2012-11-09 MX MX2014005653A patent/MX353189B/es active IP Right Grant
- 2012-11-09 ES ES12847559T patent/ES2874233T3/es active Active
- 2012-11-09 CN CN201280066355.XA patent/CN104271745A/zh active Pending
- 2012-11-09 EP EP12847559.7A patent/EP2776567B1/en active Active
- 2012-11-09 MX MX2017017128A patent/MX387666B/es unknown
- 2012-11-09 DK DK12847559.7T patent/DK2776567T3/da active
- 2012-11-09 CA CA3166278A patent/CA3166278A1/en active Pending
- 2012-11-09 BR BR112014011229-0A patent/BR112014011229B1/pt active IP Right Grant
- 2012-11-09 BR BR122019027913-6A patent/BR122019027913B1/pt active IP Right Grant
- 2012-11-09 KR KR1020147015909A patent/KR102301463B1/ko active Active
- 2012-11-09 KR KR1020197025818A patent/KR102340558B1/ko active Active
2017
- 2017-08-04 JP JP2017151540A patent/JP6657150B2/ja active Active
- 2017-08-22 US US15/683,355 patent/US11248026B2/en active Active
2018
- 2018-05-18 AU AU2018203538A patent/AU2018203538A1/en not_active Abandoned
2020
- 2020-11-03 AU AU2020264275A patent/AU2020264275B2/en active Active
2022
- 2022-02-11 US US17/670,052 patent/US12421283B2/en active Active

Also Published As

Publication number	Publication date
CN107875382A (zh)	2018-04-06
BR112014011229B1 (pt)	2021-10-13
AU2020264275B2 (en)	2023-12-14
US20230272013A1 (en)	2023-08-31
AU2018203538A1 (en)	2018-06-07
CN107875382B (zh)	2024-03-08
CN104271745A (zh)	2015-01-07
JP2015505299A (ja)	2015-02-19
US11248026B2 (en)	2022-02-15
CN111995664B (zh)	2024-08-02
US20170349634A1 (en)	2017-12-07
BR112014011229A2 (pt)	2017-05-09
CN111995664A (zh)	2020-11-27
AU2020264275A1 (en)	2020-11-26
CA3166278A1 (en)	2013-05-16
RU2019139064A (ru)	2020-01-27
AU2012335277B2 (en)	2018-06-14
KR102301463B1 (ko)	2021-09-14
US20140308308A1 (en)	2014-10-16
RU2737530C1 (ru)	2020-12-03
KR20190104644A (ko)	2019-09-10
ES2874233T3 (es)	2021-11-04
JP6232544B2 (ja)	2017-11-22
CA2889659C (en)	2023-03-14
EP3854416A1 (en)	2021-07-28
EP2776567A4 (en)	2015-12-30
KR20140095556A (ko)	2014-08-01
JP6657150B2 (ja)	2020-03-04
WO2013068847A2 (en)	2013-05-16
JP2018023374A (ja)	2018-02-15
WO2013068847A3 (en)	2014-10-30
BR122019027913B1 (pt)	2021-11-30
KR102340558B1 (ko)	2021-12-21
MX2014005653A (es)	2014-09-04
MX353189B (es)	2018-01-05
EP2776567B1 (en)	2021-01-20
MX387666B (es)	2025-03-18
EP2776567A2 (en)	2014-09-17
CA2889659A1 (en)	2013-05-16
PT2776567T (pt)	2021-05-25
US12421283B2 (en)	2025-09-23
AU2012335277A1 (en)	2014-06-12
US9777043B2 (en)	2017-10-03

Publication	Publication Date	Title
DK2776567T3 (da)	2021-04-26	Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK2929031T5 (da)	2021-08-23	Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK3252160T3 (da)	2021-02-01	Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK2898061T3 (da)	2020-02-10	Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2699553T3 (da)	2024-01-29	Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed
DK2739293T3 (da)	2020-08-24	Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK3444342T3 (da)	2020-08-24	Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
DK2768321T3 (da)	2020-08-31	Fremgangsmåder og sammensætninger til induktion af mæthed
DK3520805T3 (da)	2021-04-19	Sammensætninger til behandling af myelofibrose
DK2890780T3 (da)	2020-09-21	Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
DK3597749T3 (da)	2023-09-25	Fremgangsmåder og sammensætninger til rna-dirigeret mål-dna-modificering og til rna-dirigeret modulering af transkription
DK2691443T3 (da)	2021-05-03	Konjugerede lipomerer og anvendelser af disse
DK2872153T3 (da)	2019-05-20	Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
DK4082530T3 (da)	2024-05-06	Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme
DK2763665T3 (da)	2019-11-18	Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
DK3662932T3 (da)	2021-05-17	Anti-cgrp-sammensætninger og anvendelse deraf
DK3366307T3 (da)	2021-11-01	Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK2811876T4 (da)	2024-04-15	Kaffemaskine og fremgangsmåde til betjening af samme
DK3412687T3 (da)	2020-05-11	Fremgangsmåder til behandling af dlbcl
DK4011364T3 (da)	2024-03-18	Fremgangsmåder og sammensætninger til behandling af ADD (Attention Deficit Disorder)
DK2987507T3 (da)	2023-04-03	Fremgangsmåder til behandling af degenerative knogletilstande
DK3071215T3 (da)	2020-03-23	Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension
DK2830654T3 (da)	2019-08-26	Metoder og sammensætninger til behandling af inflammation
DK2771022T3 (da)	2020-09-28	Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
DK3007695T3 (da)	2024-03-18	Sammensætninger og fremgangsmåder til behandling af anæmi